Condition (MeSH)
Vascular Calcification
ClinicalTrials.gov lists 82 trials for Vascular Calcification or a narrower condition beneath it. Genesis Medtech Corporation has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
80 of the 82 trials are tagged with Vascular Calcification itself; the rest are tagged with a narrower condition beneath it.
When did Vascular Calcification trials start? (22)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 7
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2025 | 3 |
| 2024 | 5 |
| 2023 | 1 |
| 2022 | 2 |
| 2021 | 6 |
| 2019 | 4 |
| 2018 | 6 |
| 2017 | 5 |
| 2016 | 7 |
Showing 10 of 22 earlier years.
No forecast is made for this condition: it averages 3.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Vascular Calcification trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 1 |
| Phase 2 | 10 |
| Phase 2/3 | 1 |
| Phase 3 | 9 |
| Phase 4 | 15 |
| Not applicable | 19 |
| Observational | 25 |
How many Vascular Calcification trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 8 |
| Recruiting | 4 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 1 |
| Completed | 46 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Vascular Calcification trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Genesis Medtech Corporation | 2 |
| Abbott Medical Devices | 1 |
| Amgen | 1 |
| Ankara Ataturk Sanatorium Training and Research Hospital | 1 |
Which drugs are being tested for Vascular Calcification? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Vitamin K | 3 |
| Cinacalcet | 3 |
| Sevelamer Carbonate | 2 |
| Calcitriol | 2 |
| Antacid | 2 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Lanthanum Carbonate (Fosrenol, BAY77-1931) Granule | 3 |
| Alendronate 20 mg | 2 |
| Dialysate Magnesium (Concentration) | 2 |
| CHOLECALCIFEROL | 2 |
| No Drug | 1 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Vascular Calcification trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pneumonia | 32 | 4 |
| Renal Transplant | 31 | 1 |
| New/Worsening Wound | 16 | 1 |
| Hypertension | 15 | 3 |
| New/Worsening Infection | 15 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Vascular Calcification? (510)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Calcium Modification After Orbital Atherectomy and Balloon Angioplasty in Severely Calcified Lesions: The ECLIPSE OCT Substudy. | Circulation. Cardiovascular interventions | 2026 | Yes |
| Artificial Intelligence-derived Measurements of Myosteatosis from Coronary Artery Calcium CT Scans to Predict COPD: The Multi-Ethnic Study of Atherosclerosis. | Radiology. Cardiothoracic imaging | 2026 | Yes |
| Predicting the risk of coronary artery calcium progression in the general population: insights from the MESA and CARDIA studies. | Clinical radiology | 2025 | Yes |
| Intracoronary stenting and additional results achieved by shockWAVE coronary lithotripsy: design and rationale of ISAR-WAVE trial. | American heart journal | 2025 | Yes |
| Orbital atherectomy versus balloon angioplasty before drug-eluting stent implantation in severely calcified lesions eligible for both treatment strategies (ECLIPSE): a multicentre, open-label, randomised trial. | Lancet (London, England) | 2025 | Yes |
Showing 5 of 510 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.